TABLE 3.
Adjusted association analysis with the risk of accelerated ccIMT progression in nephrosclerosis patients.
| Gene | SNP | Genotype | SP, n (%) | AP, n (%) | OR | p |
|---|---|---|---|---|---|---|
| PLA2G7 | rs9472836 | G/G | 145 (68.4) | 60 (84.5) | 0.39 (0.19–0.80) | 0.006 |
| G/A-A/A | 67 (31.6) | 11 (15.5) | ||||
| PLA2G4A | rs72707570 | G/G | 85 (41.3) | 19 (27.1) | 2.0 (1.08–3.69) | 0.024 |
| G/C-C/C | 121 (58.7) | 51 (72.9) | ||||
| PLA2G4A | rs10578509 | T/T | 152 (76.4) | 58 (86.6) | 0.47 (0.21–1.03) | 0.045 |
| T/del-del/del | 47 (23.6) | 9 (13.4) | ||||
| PLA2G4A | rs12746200 | A/A | 161 (80.1) | 61 (89.7) | 0.44 (0.19–1.05) | 0.049 |
| A/G-G/G | 40 (19.9) | 7 (10.3) | ||||
| PLA2G4A | rs12143166 | A/A | 70 (34.8) | 33 (49.3) | 0.54 (0.31–0.-97) | 0.039 |
| A/G-G/G | 131 (65.2) | 34 (50.7) | ||||
| PLA2G4A | rs112568781 | A/A | 152 (75.2) | 43 (63.2) | 1.84 (1.01–3.34) | 0.048 |
| A/G-G/G | 50 (24.8) | 25 (36.8) |
SP, slow progression; AP, accelerated progression; OR, odds ratios with 95% confidence interval.